AKIPhase 4NCT07632469
mGFR vs tGFR in AKI
A Phase 4 study testing transdermal GFR in people with AKI and GFR, run by Bin Du.
Trial summary
The goal of this study is to learn if the TGFR device (which uses telmapirazin to continuously measure real-time GFR) works to provide accurate and dynamic kidney function assessment in critically ill adults with acute kidney injury (AKI). Read more about this study
- Who is it for?
- Ages 18 to 85 years
- What is being tested?
- transdermal GFR
- Type of treatment
- Injection or infusion, Medical device
- Could I receive a placebo?
- No, everyone receives an active treatment
- How many people
- 50 participants
- Where
- No sites listed yet
- Study dates
- 8 Jun 2026to 5 May 2027
- Phase
- Phase 4
- Are there results?
- Not yet: the study is under way
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 18 to 85 years
- All sexes
- No healthy volunteers
- Adult, Older adult
Who may be able to join
- CU stay ≤ 72 hours;
- meets KDIGO AKI criteria;
- age 18-85 years;
- able to complete blood/urine collection and monitoring
Who cannot join
- prior history of CKD stage 4 or higher;
- anuria;
- recent contrast agent exposure or kidney transplant history;
- pregnancy or breastfeeding; expected survival < 24 hours.
Trial locations and contacts
No sites are listed yet. Contact the study team or a site near you to ask about taking part.
About this study
Official title: Comparison of Agreement Between mGFR and tGFR in ICU Patients With Acute Kidney Injury
The goal of this study is to learn if the TGFR device (which uses telmapirazin to continuously measure real-time GFR) works to provide accurate and dynamic kidney function assessment in critically ill adults with acute kidney injury (AKI). It will also learn how tGFR compares with the gold standard measured GFR (mGFR) and other commonly used estimate methods. The main questions it aims to answer are:
- Does tGFR show good agreement with mGFR over the 0-12 hour period in AKI patients?
- How do tGFR, mGFR, 4-hour creatinine clearance, kinetic GFR (keGFR), and CKD-EPI eGFR compare across different AKI stages?
- What are the bias and variability of each method over time?
Read more
Researchers will compare tGFR to mGFR (iohexol clearance) to see if tGFR is a reliable alternative for bedside, continuous GFR monitoring. They will also compare tGFR against 4-hour creatinine clearance, keGFR, and eGFR to assess consistency across AKI stages.
Participants will:
- Wear a single-use tGFR sensor patch on the chest for continuous GFR monitoring
- Receive iohexol injection for mGFR measurement (gold standard)
- Provide blood and urine samples for 4-hour creatinine clearance and other tests
- Undergo repeated GFR assessments over the 12-hour study period
- Being tested
- transdermal GFR
- Keywords
- acute kidney injury, intensive care, glomerular filtration rate
- Medical subject headings
- Acute Kidney Injury
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
transdermal GFRDevice
The tGFR detection system comprised 3 distinct components as follows: (i) the fluorescent tracer agent, Lumitrace, (ii) a single small module containing both the light source and photo detector attached to the upper chest area using a biocompatible adhesive, and (iii) a display monitor that digitizes the acquired fluorescent intensity data and contains the algorithms to convert these data to GFR. Background endogenous fluorescence was acquired after attachment of the module to the chest, followed by a 7 ml i.v. bolus dose of Lumitrace. The monitor shows the fluorescence intensity as it is being acquired and then displays the determined tGFR after data acquisition is completed.
| Study group | Role | What they receive |
|---|---|---|
| intervention group | Experimental | Not described Receives: Device: transdermal GFR |
What is being measured
The primary outcome is the main question the study is designed to answer.
To validate the agreement of TGFR with mGFR in AKI patients at both the segmented and overall 0-12 hour levels.
Measured: 12 hours
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted8 Jun 2026
- Study start8 Jun 2026 (estimated)
- Primary completion31 Dec 2026 (estimated)
- Study completion5 May 2027 (estimated)
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Publications (7)Papers the sponsor has linked to this study.
- Other trials for AKIStudies of the same condition, open and under way.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Interventional
- Phase
- Phase 4
- Primary purpose
- Diagnosis
- Allocation
- Not applicable
- Intervention model
- Single group
- Masking
- None (open label)
- Enrolment
- 50 participants (estimated)
Sponsor and investigators
- Lead sponsor
- Bin Du
- Sponsor type
- University, hospital or other
- Responsible party
- Sponsor-investigator, Bin Du, Peking Union Medical College Hospital
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT07632469
- Sponsor's protocol ID
- k9467
- Status last verified
- Jun 2026
- First submitted
- 2 Jun 2026
- Last updated
- 10 Jun 2026
- Results posted
- No
- Data monitoring committee
- Yes
- FDA-regulated drug
- No
- FDA-regulated device
- No
- Individual data sharing
- No
Publications
Dorshow RB, Debreczeny MP, Goldstein SL. GFR Measurement Using Transdermal Detection Methodology. J Am Soc Nephrol. 2025 Feb 7;36(8):1592-1602. doi: 10.1681/ASN.0000000639.
PubMed 39918882Dorshow RB, Debreczeny MP, Goldstein SL, Shieh JJ. Clinical validation of the novel fluorescent glomerular filtration rate tracer agent relmapirazin (MB-102). Kidney Int. 2024 Oct;106(4):679-687. doi: 10.1016/j.kint.2024.06.012. Epub 2024 Jul 2.
PubMed 38964736Dixon JJ, Lane K, Dalton RN, Turner C, MacPhee IAM, Chis Ster I, Philips BJ. Continuous Infusion of Low-Dose Iohexol Measures Changing Glomerular Filtration Rate in Critically Ill Patients. Crit Care Med. 2018 Mar;46(3):e190-e197. doi: 10.1097/CCM.0000000000002870.
PubMed 29194145Erley CM, Bader BD, Berger ED, Vochazer A, Jorzik JJ, Dietz K, Risler T. Plasma clearance of iodine contrast media as a measure of glomerular filtration rate in critically ill patients. Crit Care Med. 2001 Aug;29(8):1544-50. doi: 10.1097/00003246-200108000-00008.
PubMed 11505124Molitoris BA. Measuring glomerular filtration rate in the intensive care unit: no substitutes please. Crit Care. 2013 Sep 4;17(5):181. doi: 10.1186/cc12876.
PubMed 24004539Inker LA, Titan S. Measurement and Estimation of GFR for Use in Clinical Practice: Core Curriculum 2021. Am J Kidney Dis. 2021 Nov;78(5):736-749. doi: 10.1053/j.ajkd.2021.04.016. Epub 2021 Sep 11.
PubMed 34518032Dorshow RB, Friedemann J, Ross-Jones J, Johnson JR, Vitale L, Riley IR, Debreczeny MP, Harr J, Trelford LP, Goldstein SL. Accuracy of Point-of-Care Transdermal GFR Methodology. Kidney Int Rep. 2026 Jan 22;11(4):103797. doi: 10.1016/j.ekir.2026.103797. eCollection 2026 Apr.
PubMed 41726007
Study at a glance
From the registry record, last updated by the sponsor on 10 Jun 2026. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- Comparison of Agreement Between mGFR and tGFR in ICU Patients With Acute Kidney Injury
- ClinicalTrials.gov ID
- NCT07632469
- Acronym / sponsor ID
- k9467
- Keywords
- acute kidney injury, intensive care, glomerular filtration rate
- Phase
- Phase 4
- Study type
- Interventional
- Recruitment status
- Not yet recruiting
- Enrolment
- 50 participants (estimated)
- Lead sponsor
- Bin DuUniversity, hospital or other
- Study start
- 8 Jun 2026 (estimated)
- Primary completion
- 31 Dec 2026 (estimated)
- Study completion
- 5 May 2027 (estimated)
- First posted
- 8 Jun 2026 (actual)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
The goal of this study is to learn if the TGFR device (which uses telmapirazin to continuously measure real-time GFR) works to provide accurate and dynamic kidney function assessment in critically ill adults with acute kidney injury (AKI). It will also learn how tGFR compares with the gold standard measured GFR (mGFR) and other commonly used estimate methods. The main questions it aims to answer are:
- Does tGFR show good agreement with mGFR over the 0-12 hour period in AKI patients?
- How do tGFR, mGFR, 4-hour creatinine clearance, kinetic GFR (keGFR), and CKD-EPI eGFR compare across different AKI stages?
- What are the bias and variability of each method over time?
Researchers will compare tGFR to mGFR (iohexol clearance) to see if tGFR is a reliable alternative for bedside, continuous GFR monitoring. They will also compare tGFR against 4-hour creatinine clearance, keGFR, and eGFR to assess consistency across AKI stages.
Participants will:
- Wear a single-use tGFR sensor patch on the chest for continuous GFR monitoring
- Receive iohexol injection for mGFR measurement (gold standard)
- Provide blood and urine samples for 4-hour creatinine clearance and other tests
- Undergo repeated GFR assessments over the 12-hour study period
Study design
- Primary purpose
- Diagnosis
- Allocation
- Not applicable
- Intervention model
- Single group
- Masking
- None (open label)
- Number of arms
- 1
| Arm | Type | Receives |
|---|---|---|
| intervention group | Experimental | Device: transdermal GFR |
Who may qualify
- Ages
- 18 to 85 years
- Sex
- All
- Healthy volunteers
- Not accepted
- Age groups
- Adult, Older adult
Key inclusion criteria (4 listed)
- CU stay ≤ 72 hours;
- meets KDIGO AKI criteria;
- age 18-85 years;
- able to complete blood/urine collection and monitoring
Key exclusion criteria (4 listed)
- prior history of CKD stage 4 or higher;
- anuria;
- recent contrast agent exposure or kidney transplant history;
- pregnancy or breastfeeding; expected survival < 24 hours.
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| transdermal GFRThe tGFR detection system comprised 3 distinct components as follows: (i) the fluorescent tracer agent, Lumitrace, (ii) a single small module containing both the light source and photo detector attached to the upper chest area using a biocompatible adhesive, and (iii) a display monitor that digitizes the acquired fluorescent intensity data and contains the algorithms to convert these data to GFR. Background endogenous fluorescence was acquired after attachment of the module to the chest, followed by a 7 ml i.v. bolus dose of Lumitrace. The monitor shows the fluorescence intensity as it is being acquired and then displays the determined tGFR after data acquisition is completed. | Device | intervention group |
Primary outcome
To validate the agreement of TGFR with mGFR in AKI patients at both the segmented and overall 0-12 hour levels.
Time frame: 12 hours
Results and safety
This study is still under way. Results are not available in the source record yet.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 10 Jun 2026.
- Results publication: PubMed 39918882Dorshow RB, Debreczeny MP, Goldstein SL. GFR Measurement Using Transdermal Detection Methodology. J Am Soc Nephrol. 2025 Feb 7;36(8):1592-1602. doi: 10.1681/ASN.0000000639.
- Results publication: PubMed 38964736Dorshow RB, Debreczeny MP, Goldstein SL, Shieh JJ. Clinical validation of the novel fluorescent glomerular filtration rate tracer agent relmapirazin (MB-102). Kidney Int. 2024 Oct;106(4):679-687. doi: 10.1016/j.kint.2024.06.012. Epub 2024 Jul 2.
- Results publication: PubMed 29194145Dixon JJ, Lane K, Dalton RN, Turner C, MacPhee IAM, Chis Ster I, Philips BJ. Continuous Infusion of Low-Dose Iohexol Measures Changing Glomerular Filtration Rate in Critically Ill Patients. Crit Care Med. 2018 Mar;46(3):e190-e197. doi: 10.1097/CCM.0000000000002870.
- Results publication: PubMed 11505124Erley CM, Bader BD, Berger ED, Vochazer A, Jorzik JJ, Dietz K, Risler T. Plasma clearance of iodine contrast media as a measure of glomerular filtration rate in critically ill patients. Crit Care Med. 2001 Aug;29(8):1544-50. doi: 10.1097/00003246-200108000-00008.
- Results publication: PubMed 24004539Molitoris BA. Measuring glomerular filtration rate in the intensive care unit: no substitutes please. Crit Care. 2013 Sep 4;17(5):181. doi: 10.1186/cc12876.
- Results publication: PubMed 34518032Inker LA, Titan S. Measurement and Estimation of GFR for Use in Clinical Practice: Core Curriculum 2021. Am J Kidney Dis. 2021 Nov;78(5):736-749. doi: 10.1053/j.ajkd.2021.04.016. Epub 2021 Sep 11.
- Results publication: PubMed 41726007Dorshow RB, Friedemann J, Ross-Jones J, Johnson JR, Vitale L, Riley IR, Debreczeny MP, Harr J, Trelford LP, Goldstein SL. Accuracy of Point-of-Care Transdermal GFR Methodology. Kidney Int Rep. 2026 Jan 22;11(4):103797. doi: 10.1016/j.ekir.2026.103797. eCollection 2026 Apr.
- Individual participant dataSharing planned: No
Related trials for AKI
Recruiting
NIRS Monitoring in the NICU and AKI
Acute Kidney Injury (AKI), Postnatal AKI
Recruiting
COordiNated CommuNication, Education, and Care Transitions After Acute Kidney Injury (CONNECT-AKI)
Acute Kidney Injury, Acute Kidney Injury (AKI)
Recruiting
Effectiveness of Remote Ischemic Preconditioning for Prevention of Contrast Induced Acute Kidney Injury in Patients Undergoing Coronary Angiograms.
Contrast-induced Acute Kidney Injury (CI-AKI) Following Coronary Angiogram (CI-AKI), Contrast-induced Nephropathy Following Coronary Angiogram (CIN)
RecruitingPhase 3
Safety Evaluation of Prismocitrate 18 in Patients Receiving CRRT
Regional Citrate Anticoagulation (RCA), Continuous Renal Replacement Therapy (CRRT)
Recruiting
Fluid Balance Guided by Modified Venous Excess Ultrasonography Versus Standard Care in Patients With Acute Kidney Injury Receiving Continuous Renal Replacement Therapy
AKI - Acute Kidney Injury, Fluid Balance
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part.
Questions about this trial
What is this clinical trial studying?
A Phase 4 study testing transdermal GFR in people with AKI and GFR, run by Bin Du.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 4 inclusion and 4 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: opening soon, as of the sponsor's last update on 10 Jun 2026. Status can change between updates, so confirm with the study contact before making plans.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
What does this phase mean?
Phase 4 studies take place after a treatment is approved, to learn more about its long-term benefits and risks in everyday use.
Not every study follows the same path, and some studies (observational studies, device studies) have no phase.
Are results available for this study?
This study is still under way. Results are not available in the source record yet.
How can a doctor refer a patient or contact the research team?
Contact Bin Du (86+69155643, dubin98@gmail.com), or a site near the patient. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
To validate the agreement of TGFR with mGFR in AKI patients at both the segmented and overall 0-12 hour levels. (time frame: 12 hours). It is what the study was designed to measure, not a finding.
Where can I read the original study information?
On the ClinicalTrials.gov record for NCT07632469, which also lists 7 linked publications.
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 10 Jun 2026; AzTrials last refreshed its copy on 26 Oct 2026.